DescriptionCurator's Comment: description was created based on several sources, including
http://www.drugbank.ca/drugs/DB00169
Curator's Comment: description was created based on several sources, including
http://www.drugbank.ca/drugs/DB00169
Cholecalciferol (/ˌkoʊləkælˈsɪfərɒl/) (vitamin D3) is one of the five forms of vitamin D. Cholecalciferol is a steroid hormone that has long been known for its important role in regulating body levels of calcium and phosphorus, in mineralization of bone, and for the assimilation of Vitamin A. The classical manifestation of vitamin D deficiency is rickets, which is seen in children and results in bony deformities including bowed long bones. Most people meet at least some of their vitamin D needs through exposure to sunlight. Ultraviolet (UV) B radiation with a wavelength of 290–320 nanometers penetrates uncovered skin and converts cutaneous 7-dehydrocholesterol to previtamin D3, which in turn becomes vitamin D3. In supplements and fortified foods, vitamin D is available in two forms, D2 (ergocalciferol) and D3 (cholecalciferol) that differ chemically only in their side-chain structure. Vitamin D2 is manufactured by the UV irradiation of ergosterol in yeast, and vitamin D3 is manufactured by the irradiation of 7-dehydrocholesterol from lanolin and the chemical conversion of cholesterol. The two forms have traditionally been regarded as equivalent based on their ability to cure rickets and, indeed, most steps involved in the metabolism and actions of vitamin D2 and vitamin D3 are identical. Both forms (as well as vitamin D in foods and from cutaneous synthesis) effectively raise serum 25(OH) D levels. Firm conclusions about any different effects of these two forms of vitamin D cannot be drawn. However, it appears that at nutritional doses, vitamins D2 and D3 are equivalent, but at high doses, vitamin D2 is less potent. The American Academy of Pediatrics (AAP) recommends that exclusively and partially breastfed infants receive supplements of 400 IU/day of vitamin D shortly after birth and continue to receive these supplements until they are weaned and consume ≥1,000 mL/day of vitamin D-fortified formula or whole milk. Cholecalciferol is used in diet supplementary to treat Vitamin D Deficiency. Cholecalciferol is inactive: it is converted to its active form by two hydroxylations: the first in the liver, the second in the kidney, to form calcitriol, whose action is mediated by the vitamin D receptor, a nuclear receptor which regulates the synthesis of hundreds of enzymes and is present in virtually every cell in the body. Calcitriol increases the serum calcium concentrations by increasing GI absorption of phosphorus and calcium, increasing osteoclastic resorption, and increasing distal renal tubular reabsorption of calcium. Calcitriol appears to promote intestinal absorption of calcium through binding to the vitamin D receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1977 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20435140 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
42 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18326608/ |
2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CALCIDIOL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
968.6 nM × day EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18326608/ |
2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CALCIDIOL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
15.5 day EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18326608/ |
2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CALCIDIOL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/10219964/ Page: 3.0 |
strong | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/10219964/ Page: 3.0 |
yes [Ki 10 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/10219964/ Page: 3.0 |
yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/15353333/ Page: 2.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15353333/ Page: 2.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15353333/ Page: 2.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15353333/ Page: 2.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15353333/ Page: 2.0 |
yes |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23612780
Purified T lymphocytes from 14 patients with systemic lupus erythematosus (SLE) and 13 healthy controls were cultured for 48 h in the presence and absence of 1 and 100 nM doses of vitamin D3.
| Substance Class |
Mixture
Created
by
admin
on
Edited
Mon Mar 31 18:57:48 GMT 2025
by
admin
on
Mon Mar 31 18:57:48 GMT 2025
|
| Record UNII |
9VU1KI44GP
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LOINC |
35365-6
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
||
|
CFR |
21 CFR 101.72
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
||
|
LOINC |
49543-2
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
||
|
DSLD |
3566 (Number of products:54)
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
||
|
CFR |
21 CFR 184.1950
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
||
|
CFR |
21 CFR 862.1825
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
||
|
WHO-ATC |
A11CC20
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
||
|
LOINC |
60493-4
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
||
|
DSLD |
3120 (Number of products:1638)
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
||
|
LIVERTOX |
NBK548094
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
||
|
LOINC |
47094-8
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
||
|
LOINC |
2236-8
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
||
|
DSLD |
1538 (Number of products:430)
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
D014807
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
PRIMARY | |||
|
1406-16-2
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
PRIMARY | |||
|
C941
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
PRIMARY | |||
|
9VU1KI44GP
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
PRIMARY | |||
|
DB11094
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
PRIMARY | |||
|
SUB129580
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
PRIMARY | |||
|
215-797-2
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
PRIMARY | |||
|
100000155487
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
PRIMARY | |||
|
9VU1KI44GP
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
PRIMARY | |||
|
DTXSID1026295
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
PRIMARY | |||
|
11253
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
PRIMARY | RxNorm | ||
|
Vitamin D
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
PRIMARY | |||
|
28934
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
PRIMARY | |||
|
SUB06596MIG
Created by
admin on Mon Mar 31 18:57:48 GMT 2025 , Edited by admin on Mon Mar 31 18:57:48 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY | |||
|
|
ACTIVE MOIETY |